GeneDx logo

GeneDx

WGS | NASDAQ
Chart Builder DCF Calculator
$51.02
-$1.35 (-2.58%)
At close: Nov 16, 2026, 4:00 PM ET
$51.00
-$0.02 (-0.04%)
After-hours: Nov 16, 2026, 7:47 PM ET
-2.58%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
53.3
Fundamentals Average
Market Sentiment Bullish
Moat Narrow
Sector Rank #209/1021 (Top 20%)

Key Statistics

Market Data

Market Cap $1.53B
1D Range
48.86 52.06
52W Range
34.51 167.52

Valuation (TTM)

PE -13.57
PB 6.25
EV/EBITDA -19.75

Valuation (NTM)

Forward PE 134.28
Forward PEG 0.19
Price Target $84.00
Loading financial charts...

Profile

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as ...

Sector Healthcare
Employees 1,300
IPO Date Nov 4, 2020
Fiscal Year January - December

Latest News

GeneDx to Participate in Upcoming Investor Conferences

5 days ago · businesswire.com

GeneDx to Participate in Upcoming Investor Conferences
Why GeneDx Holdings Stock Just Dropped 16.6%

6 days ago · fool.com

Why GeneDx Holdings Stock Just Dropped 16.6%
GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript

7 days ago · seekingalpha.com

GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript
GeneDx: Q3 Earnings Indicate Transition To Sustained Profitability

7 days ago · seekingalpha.com

GeneDx: Q3 Earnings Indicate Transition To Sustained Profitability
GeneDx Q3 Earnings Call Highlights

7 days ago · marketbeat.com

GeneDx Q3 Earnings Call Highlights
GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates

7 days ago · zacks.com

GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing

12 days ago · businesswire.com

GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
Did GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?

20 days ago · prnewswire.com

Did GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

24 days ago · businesswire.com

GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

28 days ago · businesswire.com

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

Earnings

Latest Earnings
Nov 9, 2026
EPS
$0.28
Beat +284.30%
REV
$123.1M
Beat +0.14%
Next Earnings
Feb 22, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$84.00
Upside
+64.64%
Buy (5)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.